Nardilysin regulates Slc2a2 expression through ISLET1 recruitment to an evolutionarily conserved enhancer in pancreatic β-cells

This study reveals that nardilysin (NRDC) directly regulates Slc2a2 (GLUT2) expression in pancreatic β-cells through a MafA-independent mechanism by binding to a conserved enhancer and facilitating the recruitment of the transcription factor ISLET1.

The Gist

The Big Picture: The Body's Sugar Sensor

Imagine your body is a giant factory that runs on sugar (glucose). The pancreatic beta-cells are the security guards at the factory gate. Their job is to sense how much sugar is outside and, if there's too much, release insulin (the key) to let the sugar inside to be used for energy.

To do this job, the guards need a special door called GLUT2 (or Slc2a2). This door is huge and fast, allowing sugar to rush in quickly so the guards know exactly when to release the keys. If this door is broken or missing, the guards don't realize there's a sugar rush, they don't release insulin, and the factory gets clogged with sugar. This leads to diabetes.

The Mystery: Who Controls the Door?

Scientists already knew that a protein called Nardilysin (NRDC) was essential for these guards to work. When NRDC is missing, the guards stop working, the GLUT2 doors disappear, and diabetes sets in.

However, there was a mystery:

• We knew NRDC helps make another protein called MafA, which is like a "foreman" that tells the factory to build GLUT2 doors.
• But, when NRDC was missing, the GLUT2 doors disappeared even more than just losing the foreman would explain.
• Was NRDC just helping the foreman? Or was it doing something else entirely?

The Investigation: Finding the Hidden Switch

The researchers decided to look deeper into the "blueprints" of the beta-cell. They used high-tech maps (called ATAC-seq and ChIP-seq) to find the specific switches (enhancers) that turn the GLUT2 gene on.

Think of the gene for GLUT2 as a lightbulb. The promoter is the main light switch right next to the bulb. But there are also dimmer switches (enhancers) located far away in the room that can also control how bright the light gets.

The team found four of these dimmer switches around the GLUT2 gene. Two of them were ancient, meaning they look almost exactly the same in mice and humans (evolutionarily conserved).

The Discovery: NRDC is the "Remote Control"

The team tested each of the four switches to see which one NRDC controlled.

• The Result: NRDC didn't touch the main light switch (the promoter).
• The Winner: NRDC specifically controlled one specific dimmer switch located far away from the gene, called ENH+39k.

When they removed NRDC from the cells, this specific switch went dark. The other switches stayed on. This proved that NRDC has a direct, unique job: it acts like a remote control for this specific dimmer switch.

The Mechanism: The "Bouncer" and the "VIP"

How does NRDC actually turn on this switch?

1. NRDC is the Bouncer: The researchers found that NRDC physically sits on this dimmer switch.
2. ISLET1 is the VIP: There is a famous transcription factor (a protein that turns genes on) called ISLET1. Think of ISLET1 as a VIP guest who knows how to open the door and turn on the lights.
3. The Connection: The study showed that NRDC acts like a bouncer who holds the door open specifically for ISLET1. Without NRDC, ISLET1 can't get into the room to flip the switch.

Crucially, this happens independently of the foreman (MafA). Even if the foreman is there, if the bouncer (NRDC) isn't there to let the VIP (ISLET1) in, the lights (GLUT2) stay off.

Why This Matters

This paper solves a puzzle in diabetes research. It shows that Nardilysin (NRDC) is a multitasking hero in the pancreas:

1. It helps the foreman (MafA) do his job.
2. AND it directly helps the VIP (ISLET1) turn on the GLUT2 door.

The Takeaway:
Think of NRDC as the Chief of Staff in the beta-cell. It doesn't just manage one assistant; it personally ensures that the most important switches for sugar sensing are flipped on by the right people. If this Chief of Staff is missing, the sugar-sensing system collapses, leading to diabetes. This discovery opens new doors for understanding how to fix broken sugar sensors in diabetic patients.

Technical Summary

1. Problem Statement

• Background: Glucose transporter 2 (GLUT2, encoded by Slc2a2) is the primary glucose sensor in rodent pancreatic β-cells, essential for glucose-stimulated insulin secretion (GSIS). Reduced Slc2a2 expression is a hallmark of diabetes.
• Previous Knowledge: The authors previously identified that pancreatic β-cell-specific deletion of Nardilysin (NRDC) leads to severe diabetes, defective GSIS, and reduced Slc2a2 expression. However, this phenotype was confounded by two factors:
  1. NRDC deficiency also reduces MafA, a known upstream transcriptional activator of Slc2a2.
  2. NRDC-deficient mice exhibit altered islet composition (increased α-cell/β-cell ratio) and systemic metabolic disturbances.
• The Gap: It remained unclear whether the reduction in Slc2a2 was a direct, cell-autonomous effect of NRDC deficiency or a secondary consequence of reduced MafA and altered islet architecture. Furthermore, the specific cis-regulatory mechanisms by which NRDC controls Slc2a2 transcription were unknown.

2. Methodology

The study employed a multi-faceted approach combining in vivo mouse models, in vitro cell culture, bioinformatics, and molecular biology techniques:

• Animal Models: Utilized pancreatic β-cell-specific NRDC knockout mice (BetaKO) and systemic NRDC knockout mice (Nrd1−/−).
• Cell Culture: Used the mouse pancreatic β-cell line MIN6.
  • Knockdown/Overexpression: Lentiviral vectors were used to knock down Nrd1 and overexpress Mafa.
• Bioinformatics & Genomic Analysis:
  • Integrated public ATAC-seq and ChIP-seq datasets (from ChIP-Atlas and Islet Regulome Browser) to map open chromatin and histone marks (H3K27ac) around the murine Slc2a2 locus.
  • Identified candidate enhancers and assessed evolutionary conservation between mice and humans using the ECR Browser.
• Functional Assays:
  • Luciferase Reporter Assays: Cloned candidate enhancer regions (ENH–16k, ENH–2k, ENH+4k, ENH+39k) and the promoter into vectors to test activity in MIN6 cells under NRDC knockdown conditions.
  • Chromatin Immunoprecipitation (ChIP) & Re-ChIP: Used antibodies against NRDC and ISLET1 to verify direct binding to specific genomic regions and co-occupancy.
  • qRT-PCR: Quantified mRNA levels of Slc2a2, Mafa, and Nrd1.

3. Key Contributions

• Mechanistic Decoupling: Demonstrated that NRDC regulates Slc2a2 expression in a β-cell-autonomous and MafA-independent manner.
• Enhancer Discovery: Identified a specific, evolutionarily conserved distal enhancer (ENH+39k, located 39 kb downstream of the transcription start site) as the primary target of NRDC regulation.
• Novel Molecular Interaction: Revealed that NRDC physically binds to the ENH+39k enhancer and is required for the efficient recruitment of the transcription factor ISLET1 to this site.
• Paradigm Shift: Established NRDC not just as a protease affecting protein stability, but as a direct transcriptional co-regulator of enhancer activity in β-cells.

4. Key Results

A. NRDC Regulation is Cell-Autonomous and MafA-Independent

• Knockdown of NRDC in MIN6 cells significantly reduced Slc2a2 expression, confirming cell autonomy.
• Systemic Nrd1−/− mice (which have normal islet composition) also showed reduced Slc2a2, ruling out secondary effects from islet remodeling.
• Crucial Finding: Overexpression of Mafa in NRDC-knockdown MIN6 cells restored Mafa levels but failed to rescue Slc2a2 expression. This proves NRDC regulates Slc2a2 via a pathway distinct from MafA.

B. Identification of the Critical Enhancer (ENH+39k)

• Bioinformatic analysis identified four candidate enhancers: ENH–16k, ENH–2k, ENH+4k, and ENH+39k.
• Luciferase assays confirmed all four function as enhancers.
• Selectivity: Upon NRDC knockdown, only the activity of ENH+39k was significantly suppressed. The activities of the other three enhancers and the proximal promoter were unaffected (the promoter activity actually increased, suggesting a compensatory mechanism).
• Conservation: ENH+39k is evolutionarily conserved in human islets, unlike some other candidate regions.

C. NRDC Facilitates ISLET1 Recruitment

• ChIP assays confirmed that NRDC binds directly to the ENH+39k region.
• Re-ChIP assays demonstrated that NRDC and ISLET1 co-occupy the ENH+39k enhancer.
• Mechanism: In NRDC-knockdown cells, the binding of ISLET1 to ENH+39k was significantly reduced. This indicates that NRDC acts as a scaffold or co-factor necessary to recruit ISLET1 to the enhancer to drive Slc2a2 transcription.

5. Significance

• Pathophysiological Insight: The study clarifies a dual mechanism by which NRDC deficiency causes diabetes: (1) downregulation of MafA and (2) direct impairment of Slc2a2 transcription via the ISLET1-ENH+39k axis.
• Therapeutic Potential: Identifying ENH+39k as a critical, conserved regulatory element offers a new target for restoring GLUT2 expression in diabetic conditions where MafA is compromised.
• Broader Implications: The finding that NRDC cooperates with ISLET1 suggests NRDC may function as a genome-wide cofactor for ISLET1-dependent gene regulation, potentially influencing other organs (e.g., heart) where ISLET1 is active.
• Human Relevance: The conservation of the ENH+39k enhancer and the NRDC-regulated MafA enhancer in humans suggests these mechanisms are relevant to human β-cell biology and type 2 diabetes susceptibility.

In conclusion, this paper redefines NRDC as a critical epigenetic regulator that ensures glucose sensing in β-cells by physically facilitating the assembly of the ISLET1 transcriptional complex on a conserved distal enhancer of the Slc2a2 gene.